Cliniciens, chercheurs, directeurs, cadres, personnels de recherche et des soins, partenaires industriels, ne manquez pas la première journée sur la pneumologie aux HCL le 11 juin prochain à la médiathèque santé Paul Zech HCL - Hospices Civils de Lyon Sébastien Couraud 🫁🚭🌍 Université Lyon 1 Michael Duruisseaux

@VPH_Institute Thank you to @VPH_Institute for highlighting this use case from HCL - Hospices Civils de Lyon and @novadiscovery. Kudos to Michael Duruisseaux , Claudio Monteiro and Nova team for these great results! Unprecedented in the history of modeling and simulation, this prediction underscores …

@VPH_Institute HCL - Hospices Civils de Lyon Michael Duruisseaux Claudio Monteiro … the potential of modeling approaches to accelerate drug development. These results also highlight the capabilities of the #jinkō simulation platform to efficiently conduct complex #insilico trials and provide actionable results…

@VPH_Institute HCL - Hospices Civils de Lyon Michael Duruisseaux Claudio Monteiro ❓ What's next? Michael Duruisseaux and Claudio Monteiro will present these results at ASCO during the poster session on June 3, 2024, from 1:30 PM to 4:30 PM CDT (poster #478). We hope to see many of you there!

#ASCO24 is ready to start soon! Here, my top🔟 selection with explanation, among the #LungCancer abstracts #LCSM 🧵

Fruitful collaboration with @novadiscovery and Michael Duruisseaux HCL - Hospices Civils de Lyon Have a great one at #ASCO24 sharing those impressive results! ASCO

MARIPOSA1 prognostic subgroup analysis (Dr Felip). Consistent HR benefit in all subgroups. Benefit in CNS+/- Stronger effect in liver Mets. Consistent benefit if ctDNA baseline or not or TP53 M+/not. Stronger effect if ctDNA not cleared. #ASCO24

Such a pleasure to meet patient advocate Jill Feldman and connect 🇨🇵 and 🇺🇲 patient advocacy networks. I learn a lot from talking to Jill. Patient centered research program should be our top priority! The ROS1ders, Inc. ALK Positive EGFR Resisters IFCT lung

EVOKE-01 from #ASCO24 Journal of Clinical Oncology. Phase III study of the Trop2 ADC sacituzumab govitecan vs docetaxel in NSCLC post chemo/IO. Did not meet OS endpoint (11.1 vs 9.8m, HR 0.84) but numeric improvement in squamous & non-sq. If nonresponsive to IO, OS HR 0.75 ascopubs.org/doi/10.1200/JC…

.Ines Vaz Luis, MD has received a Special Award from the ASCO for her Mentorship. The recruitment and mentorship of young colleagues involved in academic cancer care and research is a key element of the Strategic Plan of Gustave Roussy

#ASCO24 KRYSTAL-12 phase 3 study adagrasib vs. docetaxel in advanced KRASG12C+ NSCLC is positive! ▶️ Primary endpoint: PFS HR 0.58 (0.45–0.76) mPFS ADA 5.5/DOC 3.8 mo. ▶️ ORR ADA 32 vs. DOC 9% ▶️ ADA showed 🧠 efficacy ▶️ No new safety signals ▶️ OS pending ADA outperforms DOC!

#ASCO24 Say hi and stop by poster #478. In silico prediction using mechanistic models can predict actual clinical trial data. Can we use this tool to build phase III trial statistical assumption? @novadiscovery HCL - Hospices Civils de Lyon

ASCO 2024! 🚀 Claudio Monteiro and Prof. Michael Duruisseaux presented our poster at the American Society of Clinical Oncology. Our in silico approaches with jinkō have reached maturity, accelerating drug development and making it more efficient and cost-effective.

Stop pembro after 2 years? In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95. Adrien Rousseau sciencedirect.com/science/articl…

📢 Création de la nouvelle structure d'essai précoce HCL - Hospices Civils de Lyon EPSILYON (Early Phase StudIes in LYON), labellisée CLIP2 Institut national du cancer 👉recherche.chu-lyon.fr/label-clip2 Honoré de coordonner la nouvelle unité d'essai précoce tumeurs solides du GH Est

🥁Hot of the press: very pleased to share this team work "Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in 🫁cancer" Led by Thomas Pierret 🫁 and Dr Desage doi.org/10.1016/j.ctrv… OncoAlert HCL - Hospices Civils de Lyon

So happy to present our ILYAD study conducted among staffs of HCL - Hospices Civils de Lyon. In this trial we were able to precisely estimate the participation to a lung cancer screening program at 17% after 18mo of inclusion. Tanks to AstraZeneca and BD Biosciences for support. #ESMO24

Lyon s'impose en matière de recherche en cancérologie, avec un noyau dur Institut de cancérologie des HCL - Hospices Civils de Lyon, Centre Leon Berard et @CRCL Merci à Tribune de Lyon et Iris Bronner d'avoir mis en avant cette réussite tribunedelyon.fr/sciences-innov…

Très heureux d'avoir été invité à co-animer la Matinée IA et santé au cours du Sommet pour l’action sur l’Intelligence Artificielle #AIActionSummit Une discussion passionnante sur l'IA et l'accélération du développement thérapeutique Nova In Silico #AI #Innovation #FrenchTech

🥁 hot of the press new piece of work from our Lab SLX4 and XPF, two proteins involved in DNA repair, are involved in pro-tumoral properties, and may be interesting targets in solid tumors 🙏 Ligue cancer Rhône article available 👇 sciencedirect.com/science/articl… Cancer Research Center of Lyon HCL - Hospices Civils de Lyon